Palatin Technologies, Inc. (PTN) Lowered to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Palatin Technologies, Inc. (NYSE:PTN) from a buy rating to a hold rating in a research note released on Saturday morning.

According to Zacks, “Palatin Technologies, Inc is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies. “

Separately, Canaccord Genuity set a $6.00 target price on shares of Palatin Technologies and gave the stock a buy rating in a research report on Sunday, September 10th.

Shares of Palatin Technologies (NYSE:PTN) traded up 0.706% during mid-day trading on Friday, reaching $0.856. 3,182,075 shares of the company were exchanged. Palatin Technologies has a 12 month low of $0.29 and a 12 month high of $0.90. The firm’s market capitalization is $153.26 million. The company’s 50 day moving average price is $0.57 and its 200 day moving average price is $0.44.

Palatin Technologies (NYSE:PTN) last released its earnings results on Monday, September 25th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.09. The firm had revenue of $33.90 million during the quarter, compared to analysts’ expectations of $18.54 million. During the same period last year, the business earned ($0.08) earnings per share. Equities analysts anticipate that Palatin Technologies will post ($0.35) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Palatin Technologies, Inc. (PTN) Lowered to Hold at Zacks Investment Research” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://ledgergazette.com/2017/10/08/palatin-technologies-inc-ptn-lowered-to-hold-at-zacks-investment-research.html.

An institutional investor recently raised its position in Palatin Technologies stock. National Asset Management Inc. lifted its position in Palatin Technologies, Inc. (NYSE:PTN) by 46.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 315,000 shares of the biopharmaceutical company’s stock after acquiring an additional 100,000 shares during the period. National Asset Management Inc. owned about 0.23% of Palatin Technologies worth $104,000 as of its most recent SEC filing.

Palatin Technologies Company Profile

Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need

According to Zacks, “Palatin Technologies, Inc is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies. “

Separately, Canaccord Genuity set a $6.00 target price on shares of Palatin Technologies and gave the stock a buy rating in a research report on Sunday, September 10th.

Shares of Palatin Technologies (NYSE:PTN) traded up 0.706% during mid-day trading on Friday, reaching $0.856. 3,182,075 shares of the company were exchanged. Palatin Technologies has a 12 month low of $0.29 and a 12 month high of $0.90. The firm’s market capitalization is $153.26 million. The company’s 50 day moving average price is $0.57 and its 200 day moving average price is $0.44.

Palatin Technologies (NYSE:PTN) last released its earnings results on Monday, September 25th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.09. The firm had revenue of $33.90 million during the quarter, compared to analysts’ expectations of $18.54 million. During the same period last year, the business earned ($0.08) earnings per share. Equities analysts anticipate that Palatin Technologies will post ($0.35) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Palatin Technologies, Inc. (PTN) Lowered to Hold at Zacks Investment Research” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://ledgergazette.com/2017/10/08/palatin-technologies-inc-ptn-lowered-to-hold-at-zacks-investment-research.html.

An institutional investor recently raised its position in Palatin Technologies stock. National Asset Management Inc. lifted its position in Palatin Technologies, Inc. (NYSE:PTN) by 46.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 315,000 shares of the biopharmaceutical company’s stock after acquiring an additional 100,000 shares during the period. National Asset Management Inc. owned about 0.23% of Palatin Technologies worth $104,000 as of its most recent SEC filing.

Palatin Technologies Company Profile

Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Receive News & Ratings for Palatin Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply